You are here: Home

GSK

28.07.2014

New Corruption Allegations Against GSK From Syria

Allegations of corruption continue to dog British pharmaceutical company GlaxoSmithKline (GSK). The latest reports come from Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by the news agency Reuters. more
16.07.2014

Glaxo-Linked Foreign Investigators Said Indicted

Prosecutors in Shanghai have indicted Peter Humphrey, a 58-year-old UK citizen, and Yu Yingzeng, a 61-year-old US citizen, for illegally obtaining personal information on Chinese citizens, the official Chinese news agency Xinhua reports. It is the first indictment Chinese prosecutors have announced of foreigners for conducting an illegal investigation, according to Xinhua. The agency said local courts will hear the case of the two investigators at an unspecified date. more
02.07.2014

Sex Video is New Twist in GSK China Bribery Scandal

GlaxoSmithKline (GSK) has confirmed the existence of an intimate video recording of its former China head, Mark Reilly, which the London-based Sunday Times reported kicked off a bribery investigation that has damaged the pharmaceutical giant's business in China. The newspaper said the recording was shot without Reilly's knowledge or consent at his Shanghai flat and showed the Briton, who is separated from his wife, with his Chinese girlfriend. more
30.05.2014

GSK Invites Private Equity Bids for Older Drugs

UK pharmaceutical producer GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, news agencies report, citing people familiar with the matter. more
19.05.2014

Corruption Charges Against GSK Seen as Warning

Corruption charges against representatives of UK drugmaker GlaxoSmithKline (GSK) in China are a warning to other foreign firms and could do irreparable damage to the company's Chinese operations, the official Xinhua news agency said. Chinese police charged GSK's legal representative in China, Mark Reilly, and two others with corruption after a 10-month probe found that the firm made billions of yuan from bribing doctors and hospitals. more
15.04.2014

GSK Faces Criminal Bribery Investigation in Poland

GlaxoSmithKline (GSK) is facing fresh allegations of corruption, following reported incidents in China and Iraq. Polish authorities have launched a criminal investigation against the UK's biggest drugmaker for allegedly bribing doctors to promote its lung drug Seretide, also known as Advair, which has worldwide sales of around $8 billion a year. more
11.04.2014

Amgen Ends Non-U.S. Co-Marketing Pact With GSK

U.S. biotechnology firm Amgen, the world's largest, is ending its  agreement with the U.K. drugmaker GlaxoSmithkline for the marketing of its osteoporosis drug in some regions outside the U.S.. more
10.04.2014

GlaxoSmithKine Investigates Alleged Bribery in Iraq

U.K. drugmaker GlaxoSmithKine (GSK), already facing corruption accusations in China, is now investigating allegations of bribery in Iraq, the company has confirmed. The latest controversy involves claims that GSK hired Iraqi government-employed physicians and pharmacists as paid sales representatives to improperly boost use of its products. more
28.03.2014

GSK Combined Melanoma Treatment Delayed in Europe

GlaxoSmithKline (GSK), the UK's largest pharmaceutical company, has provisionally withdrawn its marketing authorization application to the European Medicines Agency (EMA) for the combined use of Tafinlar (also known as dabrafenib, Mekinist, or trametinib). more
12.03.2014

GlaxoSmithKline Offer lifts Indian Stakeholding to 75%

British drugmaker GlaxoSmithKline (GSK) said it has successfully increased its stake in its publicly-listed Indian pharmaceuticals subsidiary GlaxoSmithKline Pharmaceuticals Limited from 50.7% to 75%. The Indian firm will remain publicly-listed. more
RSS Newsletter